EGFR and non-small cell lung carcinoma: Reversible, first-generation EGFR-TKIs (gefitinib and erlotinib) clinically improved the prognosis of patients with NSCLC harboring EGFR-activating mutations (exon 19 15-base pair deletion and exon 21 L858R) [86,87].